PIK3CA and breast cancer: In another study including patients with ET-resistant (n = 15) and ET-sensitive (n = 9) breast cancer cases, the same authors were able to identify PIK3CA alterations in 55% (n = 8) and 33% (n = 3) of the cases, respectively (60).